Accumulation of immunosuppressive CD11b+ myeloid cells correlates with the failure to prevent tumor growth in the anterior chamber of the eye.

K. C. McKenna and J. A. Kapp

*J Immunol* 2006; 177:5748; doi: 10.4049/jimmunol.177.8.5748-a

http://www.jimmunol.org/content/177/8/5748.2

Figure 2B was inadvertently duplicated in Figure 3B. The corrected Figure 3 is shown below.


In the Figure 9 legend, the last sentence should reference OT-I mice, not B6.Pl mice. The corrected legend is shown below.

**FIGURE 9.** Increased numbers of CD8+ T cells and decreased numbers of CD11b+ myeloid cells is associated with delayed kinetics of tumor growth in the a.c. of OT-I mice. B6.Pl and OT-I mice (five mice/group) were injected with 10^4 E.G7-OVA in the a.c. Seven and 9 days later, tumors and indicated leukocyte populations were enumerated in collagenase-digested eyes (A). The kinetics of tumor growth and leukocyte infiltration in OT-I mice injected with 10^4 E.G7-OVA in the a.c. are shown (B). Each symbol represents the mean measurement ± 1 SD of indicated cell populations from four to nine individual mice. Day 0 values are from six untreated eyes of three OT-I mice in which 10^5 events were collected for analysis.


In Footnote 1, the word “Initiatives” in the first sentence is in error. The corrected footnote is shown below.

1This work was supported in part by an Actions Thématiques Incitatives sur Programmes grant from Centre National de la Recherche Scientifique (CNRS) (to M.D.), a grant from Association pour la Recherche sur le Cancer (to M.D.), and support from the Swedish Foundation for Strategic Research and the Swedish Research Council (to K.K. and H.S.). S.H.R. was supported by CNRS, Fondation pour la Recherche Médicale, the Philippe Foundation, and the city of Marseille. Centre d’Immunologie de Marseille-Luminy is supported by institutional grants from Institut National de la Santé et de la Recherche Médicale, CNRS, and Université de la Méditerranée.

The institution indicated for Férose Charifi is incorrect. The corrected author and affiliation lines are shown below.

Hanna Sjölin, Scott H. Robbins, Gilles Bessou, Åsa Hidmark, Elena Tomasello, Maria Johansson, Håkan Hall, Férose Charifi, Gunilla B. Karlsson Hedestam, Christine A. Biron, Klas Kärre, Petter Höglund, Eric Vivier, and Marc Dalod

*Microbiology and Tumor Biology Center and Strategic Research Center for Studies of Integrated Recognition in the Immune System, Karolinska Institute, Stockholm, Sweden; †Centre d’Immunologie de Marseille-Luminy, Université de la Méditerranée, Case 906, Marseille, France; ‡Institut National de la Santé et de la Recherche Médicale, Unité 631, Marseille, France; §Centre National de la Recherche Scientifique, Unité Mixte de Recherche 6102, Marseille, France; ¶Section of Vaccine Research, Swedish Institute for Infectious Disease Control, Solna, Sweden; and †Department of Molecular Microbiology and Immunology, Division of Biology and Medicine, Brown University, Providence, RI 02912